Developing therapies to improve quality of life in Alzheimer's disease
Established in 2016 in Heidelberg (Germany), EXCIVA is a privately held biotech company focused on developing clinical stage therapeutics for various indications in neuropsychiatry.
Our mission is to develop a groundbreaking therapy that effectively and safely addresses neuropsychiatric symptoms of dementia including agitation/aggression in Alzheimer’s disease dementia read more
​
May 12, 2026
New Chairman
Exciva appoints distinguished biopharma leader Mark Altmeyer as chairman of the board.
April 28, 2026
First Patient
Exciva doses first patient in Phase 2/3 trial of Deraphan for agitation in Alzheimer’s disease and extends Series B
round.
​​
January 20, 2026
Exciva raises €51 million
Exciva GmbH today announces the closing of a €51 million ($59m) Series B financing round.
​
​​
Our vision
We aim to improve the quality of life and independence of patients, reduce distress for caregivers and support patients' families. Through cutting-edge research, rigorous clinical trials and collaboration with experts, we are dedicated to delivering the first-in-class and best-in-class treatments for neuropsychiatric symptoms of dementia.
Our ultimate vision is to restore dignity and quality of life of individuals affected by neuropsychiatric symptoms of dementia , provide comprehensive relief, and help transform the way dementia care is perceived and managed worldwide.
​